NCT04306900 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 44
- group Id
- BG002
- value
- 25
- group Id
- BG003
- value
- 6
- group Id
- BG004
- value
- 7
- group Id
- BG005
- value
- 28
- group Id
- BG006
- value
- 17
- group Id
- BG007
- value
- 14
- group Id
- BG008
- value
- 5
- group Id
- BG009
- value
- 23
- group Id
- BG010
- value
- 8
- group Id
- BG011
- value
- 185
- units
- Participants
- groups
- description
- Participants in Cohort 1 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W on Days 1 and 15, plus budigalimab at a dose of 500 mg (Q4W) on Day 1 plus mFOLFOX6 over 48 hours (Q2W) on Day 1 and 15 of each 28-day cycle.
- id
- BG000
- title
- Cohort 1 - Safety Lead-in (TTX-030 + Budigalimab + mFOLFOX6)
- description
- Participants in Cohort 3B were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W on Days 1 and 15, plus budigalimab at a dose of 500 mg (Q4W) on Day 1 plus mFOLFOX6 over 48 hours (Q2W) on Day 1 and 15 of each 28-day cycle.
- id
- BG001
- title
- Cohort 3B - Gastric (TTX-030 + Budigalimab + mFOLFOX6)
- description
- Participants in Cohort 12 were administered IV budigalimab at a dose of 500 mg (Q4W) on Day 1 plus mFOLFOX6 over 48 hours (Q2W) on Day 1 and 15 of each 28-day cycle.
- id
- BG002
- title
- Cohort 12 - Gastric (Budigalimab + mFOLFOX6
- description
- Participants in Cohort 3A were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W on Days 1 and 15 plus mFOLFOX6 over 48 hours (Q2W) on Day 1 and 15 of each 28-day cycle.
- id
- BG003
- title
- Cohort 3A - Gastric (TTX-030 + mFOLFOX6)
- description
- Participants in Safety Lead-in Cohort 2 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W plus budigalimab 375 mg Q3W plus docetaxel at a dose of 75 mg/m2 Q3W on Day 1 of each 21-day treatment cycle.
- id
- BG004
- title
- Cohort 2 - mCRPC (TTX-030 + Budigalimab + Docetaxel)
- description
- Participants in Cohort 9 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W on Days 1 and 15 plus budigalimab at a dose of 500 mg (Q4W) on Day 1 plus gemcitabine 1000 mg/m2 + nab-paclitaxel 125 mg/m2 on Days 1, 8, and 15 each 28-day cycle.
- id
- BG005
- title
- Cohort 9 - Pancreatic (TTX-030 + Budigalimab + Gemcitabine + Nab-Paclitaxel)
- description
- Participants in Cohort 11 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W on Days 1 and 15 plus gemcitabine 1000 mg/m2 + nab-paclitaxel 125 mg/m2 on Days 1, 8, and 15 each 28-day cycle.
- id
- BG006
- title
- Cohort 11 - Pancreatic (TTX-030 + Gemcitabine + Nab-Paclitaxel)
- description
- Participants in Cohort 4 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W plus budigalimab at a dose of 375 mg Q3W on Day 1 of each 21-day treatment cycle.
- id
- BG007
- title
- Cohort 4 - CRC (TTX-030 + Budigalimab)
- description
- Participants in Cohort 6 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W plus budigalimab at a dose of 375 mg Q3W on Day 1 of each 21-day treatment cycle.
- id
- BG008
- title
- Cohort 6 - HNSCC (TTX-030 + Budigalimab)
- description
- Participants in Cohort 8 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W plus budigalimab at a dose of 375 mg Q3W on Day 1 of each 21-day treatment cycle.
- id
- BG009
- title
- Cohort 8 - GEC (TTX-030 + Budigalimab)
- description
- Participants in Cohort 10 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W plus pembrolizumab at a dose of 200 mg Q3W on Day 1 of each 21-day treatment cycle.
- id
- BG010
- title
- Cohort 10 - UCC (TTX-030 + Pembrolizumab)
- description
- Total of all reporting groups
- id
- BG011
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 31
- group Id
- BG002
- value
- 14
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 12
- group Id
- BG006
- value
- 6
- group Id
- BG007
- value
- 9
- group Id
- BG008
- value
- 3
- group Id
- BG009
- value
- 12
- group Id
- BG010
- value
- 3
- group Id
- BG011
- value
- 102
- title
- Between 18 and 65 years
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 13
- group Id
- BG002
- value
- 11
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 16
- group Id
- BG006
- value
- 11
- group Id
- BG007
- value
- 5
- group Id
- BG008
- value
- 2
- group Id
- BG009
- value
- 11
- group Id
- BG010
- value
- 5
- group Id
- BG011
- value
- 83
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Categorical
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 9.40
- value
- 65.9
- group Id
- BG001
- spread
- 12.51
- value
- 59.5
- group Id
- BG002
- spread
- 8.70
- value
- 63.2
- group Id
- BG003
- spread
- 6.28
- value
- 62.5
- group Id
- BG004
- spread
- 7.95
- value
- 65.7
- group Id
- BG005
- spread
- 6.83
- value
- 65.7
- group Id
- BG006
- spread
- 9.5
- value
- 68.2
- group Id
- BG007
- spread
- 10.57
- value
- 61.4
- group Id
- BG008
- spread
- 6.57
- value
- 65.2
- group Id
- BG009
- spread
- 15.54
- value
- 61
- group Id
- BG010
- spread
- 7.42
- value
- 66.4
- group Id
- BG011
- spread
- 10.77
- value
- 63.1
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 18
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 13
- group Id
- BG006
- value
- 6
- group Id
- BG007
- value
- 5
- group Id
- BG008
- value
- 1
- group Id
- BG009
- value
- 8
- group Id
- BG010
- value
- 1
- group Id
- BG011
- value
- 57
- title
- Female
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 26
- group Id
- BG002
- value
- 24
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 7
- group Id
- BG005
- value
- 15
- group Id
- BG006
- value
- 11
- group Id
- BG007
- value
- 9
- group Id
- BG008
- value
- 4
- group Id
- BG009
- value
- 15
- group Id
- BG010
- value
- 7
- group Id
- BG011
- value
- 128
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 25
- group Id
- BG002
- value
- 22
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 9
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 1
- group Id
- BG009
- value
- 3
- group Id
- BG010
- value
- 3
- group Id
- BG011
- value
- 69
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 2
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 1
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 9
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 17
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 6
- group Id
- BG005
- value
- 16
- group Id
- BG006
- value
- 12
- group Id
- BG007
- value
- 10
- group Id
- BG008
- value
- 3
- group Id
- BG009
- value
- 17
- group Id
- BG010
- value
- 5
- group Id
- BG011
- value
- 99
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 1
- group Id
- BG009
- value
- 2
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 8
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 24
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 8
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 1
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 3
- group Id
- BG011
- value
- 61
- title
- South Korea
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 20
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 7
- group Id
- BG005
- value
- 20
- group Id
- BG006
- value
- 15
- group Id
- BG007
- value
- 14
- group Id
- BG008
- value
- 4
- group Id
- BG009
- value
- 23
- group Id
- BG010
- value
- 5
- group Id
- BG011
- value
- 124
- title
- United States
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Region of Enrollment
- unit Of Measure
- Participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 44
- group Id
- BG002
- value
- 25
- group Id
- BG003
- value
- 6
- group Id
- BG004
- value
- 7
- group Id
- BG005
- value
- 28
- group Id
- BG006
- value
- 17
- group Id
- BG007
- value
- 14
- group Id
- BG008
- value
- 5
- group Id
- BG009
- value
- 23
- group Id
- BG010
- value
- 8
- group Id
- BG011
- value
- 185
- units
- Participants
- groups
- description
- Participants in Cohort 1 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W on Days 1 and 15, plus budigalimab at a dose of 500 mg (Q4W) on Day 1 plus mFOLFOX6 over 48 hours (Q2W) on Day 1 and 15 of each 28-day cycle.
- id
- BG000
- title
- Cohort 1 - Safety Lead-in (TTX-030 + Budigalimab + mFOLFOX6)
- description
- Participants in Cohort 3B were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W on Days 1 and 15, plus budigalimab at a dose of 500 mg (Q4W) on Day 1 plus mFOLFOX6 over 48 hours (Q2W) on Day 1 and 15 of each 28-day cycle.
- id
- BG001
- title
- Cohort 3B - Gastric (TTX-030 + Budigalimab + mFOLFOX6)
- description
- Participants in Cohort 12 were administered IV budigalimab at a dose of 500 mg (Q4W) on Day 1 plus mFOLFOX6 over 48 hours (Q2W) on Day 1 and 15 of each 28-day cycle.
- id
- BG002
- title
- Cohort 12 - Gastric (Budigalimab + mFOLFOX6
- description
- Participants in Cohort 3A were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W on Days 1 and 15 plus mFOLFOX6 over 48 hours (Q2W) on Day 1 and 15 of each 28-day cycle.
- id
- BG003
- title
- Cohort 3A - Gastric (TTX-030 + mFOLFOX6)
- description
- Participants in Safety Lead-in Cohort 2 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W plus budigalimab 375 mg Q3W plus docetaxel at a dose of 75 mg/m2 Q3W on Day 1 of each 21-day treatment cycle.
- id
- BG004
- title
- Cohort 2 - mCRPC (TTX-030 + Budigalimab + Docetaxel)
- description
- Participants in Cohort 9 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W on Days 1 and 15 plus budigalimab at a dose of 500 mg (Q4W) on Day 1 plus gemcitabine 1000 mg/m2 + nab-paclitaxel 125 mg/m2 on Days 1, 8, and 15 each 28-day cycle.
- id
- BG005
- title
- Cohort 9 - Pancreatic (TTX-030 + Budigalimab + Gemcitabine + Nab-Paclitaxel)
- description
- Participants in Cohort 11 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W on Days 1 and 15 plus gemcitabine 1000 mg/m2 + nab-paclitaxel 125 mg/m2 on Days 1, 8, and 15 each 28-day cycle.
- id
- BG006
- title
- Cohort 11 - Pancreatic (TTX-030 + Gemcitabine + Nab-Paclitaxel)
- description
- Participants in Cohort 4 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W plus budigalimab at a dose of 375 mg Q3W on Day 1 of each 21-day treatment cycle.
- id
- BG007
- title
- Cohort 4 - CRC (TTX-030 + Budigalimab)
- description
- Participants in Cohort 6 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W plus budigalimab at a dose of 375 mg Q3W on Day 1 of each 21-day treatment cycle.
- id
- BG008
- title
- Cohort 6 - HNSCC (TTX-030 + Budigalimab)
- description
- Participants in Cohort 8 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W plus budigalimab at a dose of 375 mg Q3W on Day 1 of each 21-day treatment cycle.
- id
- BG009
- title
- Cohort 8 - GEC (TTX-030 + Budigalimab)
- description
- Participants in Cohort 10 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W plus pembrolizumab at a dose of 200 mg Q3W on Day 1 of each 21-day treatment cycle.
- id
- BG010
- title
- Cohort 10 - UCC (TTX-030 + Pembrolizumab)
- description
- Total of all reporting groups
- id
- BG011
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 31
- group Id
- BG002
- value
- 14
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 12
- group Id
- BG006
- value
- 6
- group Id
- BG007
- value
- 9
- group Id
- BG008
- value
- 3
- group Id
- BG009
- value
- 12
- group Id
- BG010
- value
- 3
- group Id
- BG011
- value
- 102
- title
- Between 18 and 65 years
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 13
- group Id
- BG002
- value
- 11
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 16
- group Id
- BG006
- value
- 11
- group Id
- BG007
- value
- 5
- group Id
- BG008
- value
- 2
- group Id
- BG009
- value
- 11
- group Id
- BG010
- value
- 5
- group Id
- BG011
- value
- 83
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Categorical
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 9.40
- value
- 65.9
- group Id
- BG001
- spread
- 12.51
- value
- 59.5
- group Id
- BG002
- spread
- 8.70
- value
- 63.2
- group Id
- BG003
- spread
- 6.28
- value
- 62.5
- group Id
- BG004
- spread
- 7.95
- value
- 65.7
- group Id
- BG005
- spread
- 6.83
- value
- 65.7
- group Id
- BG006
- spread
- 9.5
- value
- 68.2
- group Id
- BG007
- spread
- 10.57
- value
- 61.4
- group Id
- BG008
- spread
- 6.57
- value
- 65.2
- group Id
- BG009
- spread
- 15.54
- value
- 61
- group Id
- BG010
- spread
- 7.42
- value
- 66.4
- group Id
- BG011
- spread
- 10.77
- value
- 63.1
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 18
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 13
- group Id
- BG006
- value
- 6
- group Id
- BG007
- value
- 5
- group Id
- BG008
- value
- 1
- group Id
- BG009
- value
- 8
- group Id
- BG010
- value
- 1
- group Id
- BG011
- value
- 57
- title
- Female
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 26
- group Id
- BG002
- value
- 24
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 7
- group Id
- BG005
- value
- 15
- group Id
- BG006
- value
- 11
- group Id
- BG007
- value
- 9
- group Id
- BG008
- value
- 4
- group Id
- BG009
- value
- 15
- group Id
- BG010
- value
- 7
- group Id
- BG011
- value
- 128
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 25
- group Id
- BG002
- value
- 22
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 9
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 1
- group Id
- BG009
- value
- 3
- group Id
- BG010
- value
- 3
- group Id
- BG011
- value
- 69
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 2
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 1
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 9
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 17
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 6
- group Id
- BG005
- value
- 16
- group Id
- BG006
- value
- 12
- group Id
- BG007
- value
- 10
- group Id
- BG008
- value
- 3
- group Id
- BG009
- value
- 17
- group Id
- BG010
- value
- 5
- group Id
- BG011
- value
- 99
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 1
- group Id
- BG009
- value
- 2
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 8
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 24
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 8
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 1
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 3
- group Id
- BG011
- value
- 61
- title
- South Korea
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 20
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 7
- group Id
- BG005
- value
- 20
- group Id
- BG006
- value
- 15
- group Id
- BG007
- value
- 14
- group Id
- BG008
- value
- 4
- group Id
- BG009
- value
- 23
- group Id
- BG010
- value
- 5
- group Id
- BG011
- value
- 124
- title
- United States
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Region of Enrollment
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle